Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Khalaf Kridin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Influenza, Human, Epstein-Barr Virus Infections, Psoriasis, Parasitic Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The risk of infections among patients with psoriasis undergoing interleukin (IL)‐23 inhibitors (IL‐23i) and IL‐17 inhibitors (IL‐17i) is yet to be exhaustively determined.
Objective
To assess the risk of infectious complications in patients with psoriasis managed by IL‐23i and IL‐17i with tumour necrosis factor inhibitors (TNFi) as a comparator.
Methods
A global cohort study comprised two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL‐23i ( n = 5272) versus TNFi ( n = 5272) and (ii) new users of IL‐17i ( n = 15,160) versus TNFi ( n = 15,160). Study groups were compared regarding the risk of 26 different infections. Propensity score matching was conducted to optimize between‐group comparability.
Results
Patients under IL‐23i had a lower risk of otitis media (HR, 0.66; 95% CI, 0.44–0.97), encephalitis (HR, 0.18; 95% CI, 0.04–0.78), herpes zoster (HZ; HR, 0.58; 95% CI, 0.41–0.82), hepatitis B virus (HBV) reactivation (HR, 0.24; 95% CI, 0.12–0.47), cytomegalovirus (HR, 0.25; 95% CI, 0.07–0.86), influenza (HR, 0.52; 95% CI, 0.38–0.71) and parasitic diseases (HR, 0.78; 95% CI, 0.64–0.95). IL‐17i was associated with a decreased risk of pneumonia (HR, 0.76; 95% CI, 0.68–0.85), septicaemia (HR, 0.84; 95% CI, 0.72–0.97), upper respiratory tract infection (HR, 0.84; 95% CI, 0.77–0.92), HZ (HR, 0.79; 95% CI, 0.67–0.92), HBV (HR, 0.59; 95% CI, 0.46–0.76) and hepatitis C virus (HR, 0.71; 95% CI, 0.57–0.88) reactivation, cytomegalovirus (HR, 0.58; 95% CI, 0.36–0.93), Epstein–Barr virus (HR, 0.38; 95% CI, 0.19–0.75), influenza (HR, 0.70; 95% CI, 0.61–0.81) and parasitic diseases (HR, 0.80; 95% CI, 0.72–0.88).
Conclusion
Compared with TNFi, IL‐23i and IL‐17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
- Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, Lübeck, Germany.
- Department of Dermatology, University of Lübeck, Lübeck, Germany.
ORCID-Profile: Khalaf Kridin
Zitieren
APA
Kridin, K., Zirpel, H., Mruwat, N., Ludwig, R. J., & Thaci, D. (2023). Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19328
Vancouver
Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19328
BibTeX
@article{Kridin2023,
author = {Kridin, Khalaf and Zirpel, Henner and Mruwat, Noor and Ludwig, Ralf J and Thaci, Diamant},
title = {Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19328}
}
EUVIMED